Kelly Valla, PharmD, BCOP, on Relapsed or Refractory Hodgkin Lymphoma: Integrating Novel Agents
Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses what advanced practitioners need to know about integrating brentuximab vedotin and PD-1 blockade earlier in the care of patients with Hodgkin lymphoma, the optimal timing of novel agents as well as new agents showing promise, and combinations that may improve outcomes.